Refine by
Ovarian Cancer Suppliers & Manufacturers
43 companies found
based inGolden, COLORADO (USA)
At Vitro Biopharma, our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market, and ultimately, to address well-established multi-billion-dollar ...
Human Ovarian Serous Cancer Associated Fibroblasts. Cryopreserved at a low passage. High passage capabilities. Expands in VitroPlusIII Low Serum, Complete Medium (Vitro Biopharma, Cat. No. PC00B1–optimized for ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
The Dolaflexin platform was designed to increase the efficacy, safety, and tolerability of ADCs. This platform overcomes the limitations of traditional ADCs in which drugs are directly conjugated to antibodies. Dolaflexin utilizes our proprietary ...
based inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
Poor Solubility and Associated Formulation and Bioavailability Difficulties. Although paclitaxel is an effective anticancer drug, its solubility is low (~ 0.4 µg/mL), which limits its medical utility to intravenous applications. Docetaxel ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Following breast cancer surgery, a HER2/neu 3+ patient receives trastuzumab (Genentech/Roche’s Herceptin, a monoclonal antibody treatment that targets the HER2/neu protein) in the first year and then hopes that their breast cancer will not ...
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
ONA-XR is an investigational medicine that prevents progesterone signaling by blocking the interaction between progesterone and its binding partner, progesterone receptor. Onapristone is the only known full PR ...
based inShirley, MASSACHUSETTS (USA)
In 2022, we became part of Absolute Biotech, a new company that unites multiple life science brands into one organization specializing in antibody reagents and services. Learn more at absolutebiotech.com. The extensive LSBio reagent catalog contains ...
LTB4R2 is a low-affinity receptor for leukotrienes including leukotriene B4. It mediates the chemotaxis of granulocytes and macrophages. The response is mediated via G-proteins that activate a phosphatidylinositol-calcium second messenger system. ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Cantrixil is a product candidate in clinical stage being developed for the treatment of ovarian cancer. Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
based inNewark, DELAWARE (USA)
ANP’s on-site technical support team is awesome! We ran into some testing problems with the NIDS multiplexed hand held assays and reader during initial testing. Upon our request, ANP immediately sent their tech support team to our test site and ...
based inNew York, NEW YORK (USA)
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic ...
Medidata AI Synthetic Control Arm (SCA®) offers the only external control arm created with cross-industry historical clinical trial data from 25,000+ clinical trials and 7 million patients. SCA can enable scientific research, cut costs and ...
based inLos Angeles, CALIFORNIA (USA)
MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer. MiraDx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D. whose cutting-edge genetic research ...
Although it is completely logical that inherited, germ-line genetic differences, present in all cells, including those of the immune system, will predict response and toxicity to developing immune therapies, there has been little study of the ...
based inÜmraniye, TURKEY
Vitrosens Biotechnology is a high-tech company in Turkey founded for the development, manufacture, and delivery of in vitro diagnostic devices (IVD) to the world. Vitrosens Biotechnology headquartered in Turkey, by a group of entrepreneurs with a ...
Test kit qualitatively detects tumor marker Carcinoembryonic Antigen (CEA) in human serum, plasma, and whole blood ...
based inRockville, MARYLAND (USA)
Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. ...
Building on the clinical advancement of VCN-01, Theriva developed the Albumin Shield™ technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration. We anticipate that this technology ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s ...
based inSaint Louis, MISSOURI (USA)
Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the ...
Sequoia is developing an anticancer compound (SQ1274) for use against solid tumors including ovarian and lung ...
based inParis, FRANCE
Oncovita is a biotech company developing a disruptive virus-derived vaccine technology to treat multiple types of cancers. Our MeasovirTM platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with ...
based inxiamen, CHINA
XIAMEN SPACEGEN Co., Ltd. is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs ，providing high-quality and accessible molecular ...
Using high-throughput sequencing to test the coding regions and exon-intron junctions of five genes (MLH1, PMS2, MSH2, MSH6, EPCAM) in the germline panel, and the same five genes plus the BRAF V600E mutation in the tissue-based panel. Detection ...
based inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...